Bevacizumab Adds Survival in Elderly Driver-Negative Lung Adenocarcinoma

This retrospective single-center analysis offers real-world survival and biomarker prognostic signals for elderly driver gene-negative lung adenocarcinoma patients receiving first-line bevacizumab plus platinum-doublet chemotherapy, but its observational design limits causal inference.

📅 Journal publication: Jul 24, 2026 · Last updated: Oct 7, 2026

bevacizumabanti-angiogenic therapyVEGF-Alung adenocarcinomadriver gene-negative NSCLCelderly oncologypemetrexedcarboplatinprognostic nutritional indexretrospective cohortPFSOS Oncology Pharmacy

Also in Geriatrics

Background Information

Bevacizumab boosts survival in elderly lung cancer patients.

Understanding treatment efficacy in elderly patients with advanced driver gene-negative lung adenocarcinoma can guide therapy decisions and improve outcomes. The median overall survival for bevacizumab plus chemotherapy was 47 months, and median progression-free survival was 24 months. This study highlights that bevacizumab combined with chemotherapy may improve survival outcomes for elderly lung adenocarcinoma patients, with biomarkers aiding in risk stratification. Bevacizumab plus chemotherapy improves survival in elderly lung adenocarcinoma patients.

📊 Deep Analysis Available

Subscribers get the full breakdown: study design, outcomes, pharmacist implications, clinical pearls, GRADE evidence grade, and a downloadable PDF report.

Subscribe for Full Access →

Authors: Li S, Wang S, Cao R

Citation: Li S, Wang S, Cao R Efficacy and prognostic factors of first-line bevacizumab plus chemotherapy in elderly patients with advanced driver gene-negative lung adenocarcinoma: A retrospective study. Medicine. 2026;105(30):e49939. doi:10.1097/MD.0000000000049939

Article Links: PubMed · Journal / DOI · Free Full Text (PMC)

🎓

Reviewed by a licensed pharmacist

Every analysis is reviewed and approved by a licensed pharmacist before publication, ensuring clinical accuracy and relevance.

Accurate and up-to-date information is our highest priority.

If you spot an error, please suggest a correction. If there is a topic you want covered, tell us and we will look at it.

Suggest a correction Request a topic

Thanks for the feedback!

🔒

Deep Analysis: Subscribers Only

Subscribers receive access to a complete clinical analysis, available online and as a downloadable PDF.

Executive Summary

Study Design

Patient Population

Primary Outcomes

Secondary Outcomes & Safety Profile

Pharmacist Implications

Clinical Pearls

Limitations

Controversies & Evidence Gaps

Cost & Logistics

Want the full analysis?

Subscribe to PharmD Signal for unrestricted access to every deep analysis, plus PDF reports, GRADE evidence grades, and pharmacist implications for every article we publish.

Become a Subscriber →